Ципрекс

General characteristics. Structure:

Active ingredient: ciprofloxacin (in the form of a hydrochloride) 250 mg

Excipients: cellulose microcrystallic, starch sodium glycollate, hydroxypropyl cellulose, silicon dioxide colloid, magnesium stearate, a cover - OY-21033.

Description. Tablets, film coated orange color.

Pharmacological properties:

Antimicrobic broad-spectrum agent of group of ftorkhinolon. Has bactericidal effect. Suppresses DNK-girazu and synthesis of bacterial DNA oppresses.

It is highly active concerning the majority of gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.

It is active concerning Staphylococcus spp. (including the strains which are producing and not producing a penicillinase, Methicillinum - resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.

Ciprofloxacin is active concerning the bacteria producing beta lactamelements.

To ciprofloxacin of a rezistentna Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides. Action concerning Treponema pallidum is studied insufficiently.

 

Pharmacokinetics. It is quickly soaked up from a GIT. Bioavailability after intake makes 70%. Meal slightly influences ciprofloxacin absorption. Linkng with proteins of plasma makes 20-40%. It is distributed in fabrics and liquids of an organism. Gets into cerebrospinal fluid: concentration of ciprofloxacin at an uninflammed meninx reach 10%, at inflamed - to 37%. High concentration are reached in bile. It is allocated with urine and bile.

Indications to use:

The infectious and inflammatory diseases caused by microorganisms, sensitive to ciprofloxacin, including respiratory diseases, an abdominal cavity and bodies of a small pelvis, bones, joints, skin; septicaemia; heavy infections of ENT organs. Treatment of postoperative infections. Prevention and treatment of infections at patients with reduced immunity.

For topical administration: acute and subacute conjunctivitis, blefarokonjyunktivita, blepharites, bacterial helcomas, keratitis, keratoconjunctivites, chronic dacryocystites, meibomites. Infectious damages of eyes after injuries or hit of foreign bodys. Preoperative prevention in an ophthalmosurgery.

Route of administration and doses:

Individual. Inside - on 250-750 mg 2 Duration of treatment - from 7-10 days to 4 weeks.

For in/in introductions a single dose - 200-400 mg, frequency rate of introduction - 2; treatment duration - 1-2 weeks, if necessary and more. It is possible to enter in/in struyno, but drop introduction within 30 min. is more preferable.

At topical administration each 1-4 h dig in 1-2 drops in the lower conjunctival sac of the affected eye. After improvement fortunes intervals between instillations can be increased.

The maximum daily dose for adults at intake makes 1.5 g.

Features of use:

Correction of the mode of dosing is required from patients with renal failures. With care apply at patients of advanced age, at atherosclerosis of vessels of a brain, disturbances of cerebral circulation, epilepsy, a convulsive syndrome of not clear etiology.

During treatment patients have to receive enough liquid.

In case of persistent diarrhea ciprofloxacin should be cancelled.

At simultaneous in administration of ciprofloxacin and barbiturates control of ChSS, the ABP, an ECG is necessary. In the course of treatment control of concentration in blood of urea, creatinine, hepatic transaminases is necessary.

During treatment decrease in reactionary ability (is possible especially at simultaneous use with alcohol).

Administration of ciprofloxacin subkonjyunktivalno or directly in an anterior chamber of an eye is not allowed.

Side effects:

From the alimentary system: nausea, vomiting, diarrhea, abdominal pains, increase in activity of hepatic transaminases, ShchF, LDG, bilirubin, pseudomembranous colitis.

From TsNS: headache, dizziness, feeling of fatigue, frustration of a dream, dreadful dreams, hallucinations, faints, visual disturbances.

From an urinary system: crystalluria, glomerulonephritis, dysuria, polyuria, albuminuria, hamaturia, tranzitorny increase in content in creatinine blood serum.

From system of a hemopoiesis: eosinophilia, leukopenia, neutropenia, change of quantity of thrombocytes.

Co of the party of cardiovascular system: tachycardia, disturbances of a cordial rhythm, arterial hypotension.

Allergic reactions: skin itch, small tortoiseshell, Quincke's edema, Stephens-Johnson's syndrome, arthralgias.

The side reactions connected with chemotherapeutic action: candidiasis.

Local reactions: morbidity, phlebitis (at in introduction). At use of eye drops easy morbidity and a hyperemia of a conjunctiva are in certain cases possible.

Others: vasculitis.

Interaction with other medicines:

At simultaneous use of ciprofloxacin with didanoziny absorption of ciprofloxacin decreases owing to formation of complexons of ciprofloxacin with the aluminum and magnesian buffers which are contained in the didanozena.

At simultaneous use with warfarin the risk of development of bleeding increases.

At simultaneous use of ciprofloxacin and theophylline increase in concentration of theophylline in a blood plasma, to increase in T1/2 of theophylline is possible that leads to increase in risk of development of the toxic action connected with theophylline.

The concomitant use of antacids, and also the drugs containing ions of aluminum, zinc, iron or magnesium can cause decrease in absorption of ciprofloxacin therefore the interval between purpose of these drugs has to be not less than 4 h.

Contraindications:

Pregnancy, lactation (breastfeeding), children's and teenage age up to 15 years, hypersensitivity to ciprofloxacin and other drugs of a hinolonovy row.

Use at pregnancy and feeding by a breast
It is contraindicated at pregnancy, in the period of a lactation.

Ciprofloxacin gets through a placental barrier, is emitted with breast milk.

In pilot studies it is established that it causes an arthropathy.

Use at renal failures
Correction of the mode of dosing is required from patients with renal failures.

Use for elderly patients
With care apply at patients of advanced age.

Use for children
It is contraindicated at children's and teenage age up to 15 years.

Issue conditions:

According to the recipe

Packaging:

Tablets of 250 mg 10 - blisters (1) - packs cardboard.

Tablets of 500 mg 10 - blisters (1) - packs cardboard.

Tablets of 750 mg 10 - blisters (1) - packs cardboard.